Mathematical Model of MMC Chemotherapy for Non-invasive Bladder Cancer Treatment

Overview

Journal Front Oncol

Specialty Oncology

Date 2024 Jun 17

PMID 38884094

Authors

Marom Yosef

Svetlana Bunimovich-Mendrazitsky

Affiliations

Soon will be listed here.

Abstract

Mitomycin-C (MMC) chemotherapy is a well-established anti-cancer treatment for non-muscle-invasive bladder cancer (NMIBC). However, despite comprehensive biological research, the complete mechanism of action and an ideal regimen of MMC have not been elucidated. In this study, we present a theoretical investigation of NMIBC growth and its treatment by continuous administration of MMC chemotherapy. Using temporal ordinary differential equations (ODEs) to describe cell populations and drug molecules, we formulated the first mathematical model of tumor-immune interactions in the treatment of MMC for NMIBC, based on biological sources. Several hypothetical scenarios for NMIBC under the assumption that tumor size correlates with cell count are presented, depicting the evolution of tumors classified as small, medium, and large. These scenarios align qualitatively with clinical observations of lower recurrence rates for tumor size ≤ 30[mm] with MMC treatment, demonstrating that cure appears up to a theoretical [mm] tumor size threshold, given specific parameters within a feasible biological range. The unique use of mole units allows to introduce a new method for theoretical pre-treatment assessments by determining MMC drug doses required for a cure. In this way, our approach provides initial steps toward personalized MMC chemotherapy for NMIBC patients, offering the possibility of new insights and potentially holding the key to unlocking some of its mysteries.

References

Schooneveldt G, Kok H, Bakker A, Geijsen E, Rasch C, de la Rosette J . Clinical validation of a novel thermophysical bladder model designed to improve the accuracy of hyperthermia treatment planning in the pelvic region. Int J Hyperthermia. 2018; 35(1):383-397. DOI: 10.1080/02656736.2018.1506164. View

Chen S, Chung C, Cheng Y, Huang C, Ruaan R, Chen W . Hydrostatic pressure enhances mitomycin C induced apoptosis in urothelial carcinoma cells. Urol Oncol. 2013; 32(1):26.e17-24. DOI: 10.1016/j.urolonc.2012.09.004. View

Shaikhet L, Bunimovich-Mendrazitsky S . Stability Analysis of Delayed Immune Response BCG Infection in Bladder Cancer Treatment Model by Stochastic Perturbations. Comput Math Methods Med. 2018; 2018:9653873. PMC: 6076981. DOI: 10.1155/2018/9653873. View

Kim L, Patel M . Transurethral resection of bladder tumour (TURBT). Transl Androl Urol. 2021; 9(6):3056-3072. PMC: 7807319. DOI: 10.21037/tau.2019.09.38. View

Nave O, Hareli S, Elbaz M, Iluz I, Bunimovich-Mendrazitsky S . BCG and IL - 2 model for bladder cancer treatment with fast and slow dynamics based on SPVF method-stability analysis. Math Biosci Eng. 2019; 16(5):5346-5379. DOI: 10.3934/mbe.2019267. View

Logan C, Brown M, Hayne D . Intravesical therapies for bladder cancer - indications and limitations. BJU Int. 2012; 110 Suppl 4:12-21. DOI: 10.1111/j.1464-410X.2012.11619.x. View

Li Y, Lin K, Yang Z, Han N, Quan X, Guo X . Bladder cancer stem cells: clonal origin and therapeutic perspectives. Oncotarget. 2017; 8(39):66668-66679. PMC: 5630446. DOI: 10.18632/oncotarget.19112. View

Babjuk M, Burger M, Comperat E, Gontero P, Mostafid A, Palou J . European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol. 2019; 76(5):639-657. DOI: 10.1016/j.eururo.2019.08.016. View

Ho P, Kurtova A, Chan K . Normal and neoplastic urothelial stem cells: getting to the root of the problem. Nat Rev Urol. 2012; 9(10):583-94. PMC: 3468664. DOI: 10.1038/nrurol.2012.142. View

10.

Bunimovich-Mendrazitsky S, Gluckman J, Chaskalovic J . A mathematical model of combined bacillus Calmette-Guerin (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancer. J Theor Biol. 2011; 277(1):27-40. DOI: 10.1016/j.jtbi.2011.02.008. View

11.

Malmstrom P, Sylvester R, Crawford D, Friedrich M, Krege S, Rintala E . An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009; 56(2):247-56. DOI: 10.1016/j.eururo.2009.04.038. View

12.

Griffiths T . Current perspectives in bladder cancer management. Int J Clin Pract. 2012; 67(5):435-48. DOI: 10.1111/ijcp.12075. View

13.

Friedman A, Lai X . Combination therapy for cancer with oncolytic virus and checkpoint inhibitor: A mathematical model. PLoS One. 2018; 13(2):e0192449. PMC: 5805294. DOI: 10.1371/journal.pone.0192449. View

14.

Hori S, Miyake M, Tatsumi Y, Onishi S, Morizawa Y, Nakai Y . Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model. PLoS One. 2017; 12(4):e0175494. PMC: 5391151. DOI: 10.1371/journal.pone.0175494. View

15.

Nolz J . Molecular mechanisms of CD8(+) T cell trafficking and localization. Cell Mol Life Sci. 2015; 72(13):2461-73. PMC: 4458431. DOI: 10.1007/s00018-015-1835-0. View

16.

Dudley M, Wunderlich J, Robbins P, Yang J, Hwu P, Schwartzentruber D . Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002; 298(5594):850-4. PMC: 1764179. DOI: 10.1126/science.1076514. View

17.

Joseph M, Enting D . Immune Responses in Bladder Cancer-Role of Immune Cell Populations, Prognostic Factors and Therapeutic Implications. Front Oncol. 2019; 9:1270. PMC: 6879653. DOI: 10.3389/fonc.2019.01270. View

18.

Lee S, Hu W, Matulay J, Silva M, Owczarek T, Kim K . Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer. Cell. 2018; 173(2):515-528.e17. PMC: 5890941. DOI: 10.1016/j.cell.2018.03.017. View

19.

Jeong C, Jeon H, Kwak C, Jeong H, Lee S . Comparison of 30 mg and 40 mg of mitomycin C intravesical instillation in Korean superficial bladder cancer patients: prospective, randomized study. Cancer Res Treat. 2009; 37(1):44-7. PMC: 2785421. DOI: 10.4143/crt.2005.37.1.44. View

20.

Zargar H, Aning J, Ischia J, So A, Black P . Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer. Nat Rev Urol. 2014; 11(4):220-30. DOI: 10.1038/nrurol.2014.52. View